GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relypsa Inc (NAS:RLYP) » Definitions » Return-on-Tangible-Equity

Relypsa (Relypsa) Return-on-Tangible-Equity : -226.64% (As of Jun. 2016)


View and export this data going back to 2013. Start your Free Trial

What is Relypsa Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Relypsa's annualized net income for the quarter that ended in Jun. 2016 was $-334.46 Mil. Relypsa's average shareholder tangible equity for the quarter that ended in Jun. 2016 was $147.58 Mil. Therefore, Relypsa's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2016 was -226.64%.

The historical rank and industry rank for Relypsa's Return-on-Tangible-Equity or its related term are showing as below:

RLYP's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -46.56
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Relypsa Return-on-Tangible-Equity Historical Data

The historical data trend for Relypsa's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relypsa Return-on-Tangible-Equity Chart

Relypsa Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15
Return-on-Tangible-Equity
- - - -82.66 -117.83

Relypsa Quarterly Data
Dec11 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.02 -82.13 -113.04 -118.68 -226.64

Competitive Comparison of Relypsa's Return-on-Tangible-Equity

For the Biotechnology subindustry, Relypsa's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relypsa's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relypsa's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Relypsa's Return-on-Tangible-Equity falls into.



Relypsa Return-on-Tangible-Equity Calculation

Relypsa's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2015 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2015 )  (A: Dec. 2014 )(A: Dec. 2015 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2015 )  (A: Dec. 2014 )(A: Dec. 2015 )
=-178.716/( (118.461+184.873 )/ 2 )
=-178.716/151.667
=-117.83 %

Relypsa's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2016 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2016 )  (Q: Mar. 2016 )(Q: Jun. 2016 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2016 )  (Q: Mar. 2016 )(Q: Jun. 2016 )
=-334.464/( (184.234+110.92)/ 2 )
=-334.464/147.577
=-226.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2016) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Relypsa  (NAS:RLYP) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Relypsa Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Relypsa's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Relypsa (Relypsa) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Relypsa Inc is a biopharmaceutical company engaged in the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases.
Executives
Ronald A. Krasnow officer: See Remarks C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kristine M Ball officer: Chief Financial Officer & SVP C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mcgirr David W J director 33 PHEASANT LANE, GREENWICH CT 06830
Paul J Hastings director 61 HARTFORD STREET, SAN FRANCISCO CA 94114
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Wilhelm Stahl officer: SVP, Chief Technology Officer C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
J. Scott Garland officer: SVP & Chief Commercial Officer 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Helen Torley director C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Relypsa (Relypsa) Headlines

From GuruFocus

Insiders Buy Stock in Wynn Resorts, Bank of New York Mellon

By Tiziano Frateschi Tiziano Frateschi 10-26-2015